Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Yuexin Cheng"'
Autor:
Lingling Wang, Lei Yang, Fangshu Guan, Jing Chen, Yuexin Cheng, Yuqing Miao, Jingsong He, Zhen Cai, He Huang, Yi Zhao
Publikováno v:
Cancer Medicine, Vol 13, Iss 14, Pp n/a-n/a (2024)
Abstract There are limited studies on mutation profiling for Peripheral T‐cell lymphomas (PTCL) in the Chinese population. We retrospectively analyzed the clinical and genetic landscape of 66 newly diagnosed Chinese patients. Targeted next‐genera
Externí odkaz:
https://doaj.org/article/7a17475de33e4f16883b578711361d09
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundFamilial 46, XY Disorder of Sexual Development (DSD) was discovered in a Ph+, BCR::ABL1P210+ Acute Lymphoblastic Leukemia (ALL) female with RCBTB2::LPAR6 fusion gene. Siblings developing 46, XY DSD are extremely rare. Patients with 46, XY D
Externí odkaz:
https://doaj.org/article/958fb8007e7d4e829ad8997c63b3e992
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Waldenstrom’s macroglobulinemia (WM) is a rare and indolent B-cell lymphoma. To investigate the type and survival of hematologic secondary malignancies (SMs) in Chinese patients with WM, we retrospectively reviewed the characteristics of 102 patien
Externí odkaz:
https://doaj.org/article/b86b130c02f74412877f678a7a2741ab
Autor:
Lingling Wang, Qian Huang, Jiao Tang, Jun Feng, Yongfen Huang, Jianming Dong, Yuexin Cheng, Hao Xu, Yuqing Miao
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Nodal Marginal Zone Lymphoma(NMZL) is an indolent lymphoma with a very low clinical incidence and is sometimes difficult to differentiate diagnostically from Lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia (LPL/WM). NMZL with elevated monocl
Externí odkaz:
https://doaj.org/article/f39f32908ece4ce69f5b2f53f29f3e25
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
BackgroundWaldenstrom Macroglobulinemia (WM) is a rare and indolent lymphoma of B-cell origin characterized by elevated monoclonal IgM, with MYD88L265P mutation and CXCR4 mutation as common molecular alterations. B-cell Acute Lymphoblastic Leukemia (
Externí odkaz:
https://doaj.org/article/fb1fb7f5c6304783b8162f82a6627bba
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Zanubrutinib, a next-generation non-covalent Bruton’s tyrosine kinase (BTK) inhibitor, shows great efficacy in the treatment of B cell malignancies. Some patients may experience a series of side effects after the treatment of zanubrutinib. Grade 4
Externí odkaz:
https://doaj.org/article/9f91a2d6c6eb489990c5a6df162922cd
Publikováno v:
Frontiers in Oncology; 2024, p1-8, 8p
Autor:
Xiaodong Lyu, Tao Li, Dandan Zhu, Yuexin Cheng, Yan Chen, Xiangxiang He, Zhenling Li, Shiyong Li, Wei Wu, Shuaipeng Geng, Mengna Zhang, Chunxiao Yao, Jingshuai Li, Yangwei Li, Yinyin Chang, Yuchun Li, Zunmin Zhu, Mao Mao, Yongping Song
Publikováno v:
Leukemia & Lymphoma. 63:2301-2310
Copy number aberrations (CNA) are the core determinants for diagnosis, risk stratification and prognosis in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In this study, a shallow whole-genome sequencing-based assay, LeukoPrint, was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d77984af59afddcd17b3ecc20a3060fd
https://doi.org/10.1080/10428194.2022.2080821
https://doi.org/10.1080/10428194.2022.2080821
Autor:
Miao Qing, Yongfen Huang, Can Chen, Lingling Wang, Jun Feng, Chuanhai Xu, Yuexin Cheng, Jianming Dong, Linlin Zhang, Hao Xu
Publikováno v:
Blood. 140:3769-3770
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::12e6006cdc03d9b999ee3868ac928a0e
https://doi.org/10.1182/blood-2022-167998
https://doi.org/10.1182/blood-2022-167998
Autor:
Xiaodong Lyu, Tao Li, Dandan Zhu, Mengna Zhang, Yuexin Cheng, Yan Chen, Zhenling Li, Shiyong Li, Wei Wu, Shuaipeng Geng, Jingshuai Li, Xiangxiang He, Yangwei Li, Yinyin Chang, Zunmin Zhu, Mao Mao, Yongping Song
Publikováno v:
Cancer Research. 82:5263-5263
Genomic alternations especially copy number aberrations (CNAs) are particularly imperative for diagnostic classification and risk stratification in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). Although conventional c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ff9c6fe5228096a8b0e400a49c8fd3b
https://doi.org/10.1158/1538-7445.am2022-5263
https://doi.org/10.1158/1538-7445.am2022-5263